Views: 0 Author: Site Editor Publish Time: 2026-07-10 Origin: Site
News Release – July 10, 2026
On July 3, 2026, the 2025–2026 Pharmaceutical Industry Information Conference, hosted by the All-China Federation of Industry and Commerce Pharmaceutical Chamber of Commerce and the Haikou National High‑tech Industrial Development Zone Management Committee, was successfully held in Haikou, Hainan. Bestcomm Pharmaceutical was invited to attend the conference.
During the awards ceremony, Bestcomm (parent company of Loncom Pharmaceutical) stood out for its outstanding performance in pharmaceutical R&D and its strong industry reputation, winning two prestigious honors:
"2025–2026 Pharmaceutical Industry Independent Innovation Enterprise"
"2025–2026 Top 50 Pharmaceutical R&D Enterprises"
As a one‑stop integrated solution provider for new drug R&D, Bestcomm has established a comprehensive R&D service system covering active pharmaceutical ingredients (APIs), formulations, and sustained‑release/controlled‑release technologies. The company has previously received numerous accolades, including "National Technology Transfer Demonstration Institution," "National High‑tech Enterprise," "China Technology Market Golden Bridge Award," and "2026 Top 20 Chinese Pharmaceutical CRO Enterprises." It has also been consecutively selected for the "Top 50 Pharmaceutical R&D Enterprises" ranking for three consecutive years.
Looking ahead, Bestcomm will continue to enhance its R&D service capabilities, leverage its technological platform strengths to help partners accelerate innovative drug development, and provide more patients with high‑quality pharmaceutical options.
